Compare DexCom, Inc. (DXCM) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SoundHound AI Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: DexCom, Inc. is far larger — about 13× SoundHound AI Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and SoundHound AI Inc for 23 Days on average.
| DXCM | SOUN | |
|---|---|---|
Market Cap | $31.86B | $2.45B |
Volume | 3,607,070 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $92.34 | $21.40 |
52-Week Low | $54.84 | $5.39 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
SoundHound AI (SOUN) trades at $5.52, down 1.95% amid bearish technical signals despite recent earnings beats. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, but faces significant profitability challenges with a -67.45% net income margin. Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices.
While analyst consensus remains bullish with a $9.33 price target (75% buy ratings), the stock faces headwinds from persistent losses, negative cash flow projections for 2026, and insider selling activity. The key investment thesis hinges on voice AI adoption growth versus the company's ability to achieve profitability amid high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
